Research programme: lobeline analogues - Yaupon TherapeuticsAlternative Names: Lobelane
Latest Information Update: 12 Jan 2012
At a glance
- Originator Yaupon Therapeutics
- Developer Ceptaris Therapeutics
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Drug abuse
Most Recent Events
- 08 Jan 2012 Discontinued - Preclinical for Drug abuse in USA (unspecified route)
- 07 Nov 2007 Preclinical trials in Drug abuse in USA (unspecified route)